微电生理(688351) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥89,152,510.16, representing a year-on-year increase of 71.01%[18] - The net profit attributable to shareholders for Q1 2024 was ¥4,169,185.75, with a non-applicable year-on-year comparison[18] - Total operating revenue for Q1 2024 reached ¥89,152,510.16, a significant increase from ¥52,132,729.40 in Q1 2023, representing a growth of approximately 70.9%[37] - The net profit for Q1 2024 was ¥4,169,185.75, a recovery from a net loss of ¥9,326,097.49 in Q1 2023[39] - The total comprehensive income attributable to the parent company was 4,169,185.75, compared to a loss of 9,326,097.49 in the previous period[40] - Basic and diluted earnings per share were both 0.0089, an improvement from -0.0198 in the prior period[40] Assets and Liabilities - The total assets at the end of Q1 2024 were ¥1,843,460,584.28, reflecting a 1.11% increase from the end of the previous year[4] - The total liabilities of the company rose to ¥152,593,267.14, an increase from ¥138,210,343.16, reflecting a growth of approximately 10.5%[51] - The total owner's equity amounted to ¥1,690,867,317.14, slightly increasing from ¥1,685,058,042.94, showing a marginal growth of about 0.2%[51] - The company's non-current liabilities decreased to ¥38,581,071.98 from ¥41,774,873.20, a reduction of approximately 7.3%[51] - The company's estimated liabilities increased to ¥7,354,530.53 from ¥6,965,750.90, reflecting a growth of about 5.6%[51] Cash Flow - The net cash flow from operating activities for Q1 2024 was ¥6,260,970.00[18] - Net cash flow from operating activities was 6,260,970.00, a significant recovery from -13,787,510.55 in the previous period[41] - Cash inflow from investment activities totaled 1,069,080,977.50, up from 815,531,312.04 in the prior period[41] - Net cash flow from investment activities was 129,739,268.51, a recovery from -258,807,625.67 in the previous period[41] - The total cash and cash equivalents at the end of the period increased to 389,381,721.01, compared to 302,819,817.79 at the end of the previous period[43] Research and Development - Research and development expenses totaled ¥23,197,241.84, a decrease of 14.09% compared to the previous period[4] - The proportion of R&D expenses to operating revenue was 26.02%, down by 25.77 percentage points[4] - Research and development expenses for Q1 2024 amounted to ¥19,762,555.02, down from ¥23,452,627.63 in Q1 2023, reflecting a decrease of approximately 15.5%[37] Market Expansion and Sales - The company actively expanded its domestic and international markets, leading to a significant increase in product sales compared to the same period last year[23] - Sales revenue from goods and services received cash of ¥95,031,214.55 in Q1 2024, compared to ¥70,584,284.89 in Q1 2023, indicating a year-over-year increase of about 34.8%[56] Shareholder Information - The number of shares held by the top 10 shareholders includes significant stakes from various investment funds, with the largest being 23,139,884 shares held by Shanghai Yuheng Investment Management Center[27] - The company has engaged in securities lending, with 202,400 shares lent out by Shanghai Zhangjiang Torch Venture Capital Co., Ltd.[27]